Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,202 across all filing types
Latest filing 2023-02-16 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
股东减持股份进展公告
Transaction in Own Shares Classification · 95% confidence The document is a formal announcement regarding the progress of a shareholder's reduction in shareholding in the company. It details the shareholder's holdings before and after the reduction, the method and timing of the share sales, and compliance with relevant securities laws and regulations. There is no financial performance data, no discussion of company management or board changes, no earnings or annual report content, and no mention of legal proceedings or mergers. The document is specifically about a shareholder's transaction in their own shares, i.e., a reduction in holdings. Therefore, it fits the category of 'Transaction in Own Shares' (POS). The document length is under 5,000 characters and is a direct announcement of the shareholding change, not a report publication or regulatory filing. Confidence is high due to clear content and context.
2023-02-16 Chinese
东方金诚国际信用评估有限公司关于灵康药业集团股份有限公司2022年年度业绩预亏的关注公告
Regulatory Filings
2023-02-14 Chinese
灵康药业集团股份有限公司回购报告书
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding a share repurchase plan. It includes specifics about the repurchase amount, price, purpose (employee stock ownership plan and equity incentive plan), authorization, risks, and impact analysis. The document is not a financial report but a formal disclosure about the company's plan to buy back its own shares. It does not contain financial statements or earnings data but focuses on the share repurchase program details. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which covers share repurchase announcements and related disclosures.
2023-02-01 Chinese
关于回购事项前十名股东持股信息的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding the shareholding information of the top ten shareholders prior to a share repurchase plan. It includes detailed tables of the top ten shareholders and their shareholding percentages as of a specific date. The document references a board meeting approving a share repurchase plan and discloses shareholding data relevant to that repurchase. This fits the category of a Transaction in Own Shares (POS) report, which covers company buybacks or sales of its own shares. The document length is short and focused solely on shareholding information related to the repurchase, not a full financial report or other types of filings.
2023-02-01 Chinese
2022年年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2022 annual earnings forecast (业绩预告) for Lingkang Pharmaceutical Group Co., Ltd. It provides preliminary estimated net profit figures for the full year 2022, including expected losses, and notes that the data is unaudited and preliminary. It explicitly states that the final accurate financial data will be disclosed in the formal 2022 annual report. The document length is short (1028 characters) and it is a forecast or preliminary earnings guidance rather than a full financial report. This fits the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. It is not a full Annual Report (10-K) or Interim Report (IR) because it lacks comprehensive financial statements and detailed analysis. It is not a Report Publication Announcement (RPA) because it contains substantive preliminary financial data, not just a notice of report availability. FY 2022
2023-01-30 Chinese
关于以集中竞价交易方式回购公司股份方案的公告
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding a share repurchase plan through centralized bidding transactions. It includes specifics about the purpose of the repurchase, amount and source of funds, price limits, repurchase period, impact analysis, and authorization details. The document does not contain financial statements or quarterly/yearly financial results but focuses on the company's plan to buy back its own shares for employee stock ownership and equity incentive plans. This matches the definition of a Transaction in Own Shares (POS) filing, which reports on the company buying back its own shares. The document length is over 6,000 characters and contains substantive details about the repurchase plan, not just an announcement of a report publication or a regulatory filing. Therefore, the correct classification is POS with high confidence.
2023-01-30 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.